SPDR SSGA Multi-Asset Real Return ETF (RLY)
ARCA ARCA Primary 
Relay Therapeutics Is A Buy For Its Superb Safety Data
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rates and significantly lower toxicity compared to existing therapies like alpelisib and inavolisib. The Eli Lilly acquisition of STX-478 from Scorpion Therapeutics highlights the value of allosteric PI3Kα inhibitors, positioning RLAY as undervalued and ahead in clinical development.
Relay Therapeutics: A Precision Oncology Play Worth The Risk
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials.
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion opportunities of the RLY-2608 program includes two triplet regimens targeting 1st-line PI3Ka-mutant HR+/HER2- breast cancer patients and phase 1 study for tumors with vascular formations starting in Q1 2025.
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company's RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials and a commercialization partner to unlock broader market potential.
RLY: A Nice Allocation Fund
Asset allocation is still important despite recent performance trends. SPDR® SSgA Multi-Asset Real Return ETF offers a mix of asset class exposure for real returns. The RLY ETF focuses on inflation-protected securities, real estate securities, commodities, and infrastructure companies.
